

Table 1.24
Age-Adjusted SEER Incidence Rates and Trends for the Top 15 Cancer Sites^a by Race/Ethnicity
Both Sexes

	All Races		White		Black	
	Rate ^b 2006-2010	APC ^c 2001-2010	Rate ^b 2006-2010	APC ^c 2001-2010	Rate ^b 2006-2010	APC ^c 2001-2010
All Sites	463.0	-0.6*	471.9	-0.6*	483.6	-1.0*
Prostate ^f	68.6	-1.9*	68.0	-1.0*	96.3	-2.1*
Breast	66.8	-0.8*	66.1	-2.0*	69.7	-1.7*
Lung and Bronchus	61.4	-1.5*	63.1	-1.4*	69.3	0.3
Colon and Rectum	45.0	-2.6*	44.2	-2.8*	55.3	-2.3*
Melanoma of the Skin	21.1	1.5*	25.0	1.6*	17.4	2.9*
Urinary Bladder	20.7	-0.6*	22.5	-0.6*	15.8	0.5
Non-Hodgkin Lymphoma	19.7	0.1	20.7	0.1	14.2	-0.2
Kidney and Renal Pelvis	15.3	2.4*	15.8	2.3*	12.7	1.7*
Corpus and Uterus, NOS ^f	13.0	0.6	13.5	-0.5*	12.5	-0.2
Leukemia	12.8	-0.5*	13.3	0.4	11.9	0.3
Pancreas	12.2	0.9*	13.0	6.4*	11.6	-1.8*
Thyroid	12.2	6.3*	12.1	1.0*	9.8	-1.7*
Oral Cavity and Pharynx	10.8	0.2	11.2	0.5*	9.6	-2.5*
Liver & IBD ^g	7.7	3.6*	7.1	-0.2	9.1	3.7*
Stomach	7.5	-1.1*	7.1	-1.9*	7.1	5.7*
	Asian/Pacific Islander		American Indian/Alaska Native ^d		Hispanic ^e	
	Rate ^b 2006-2010	APC ^c 2001-2010	Rate ^b 2006-2010	APC ^c 2001-2010	Rate ^b 2006-2010	APC ^c 2001-2010
All Sites	307.4	-0.9*	323.6	-0.6	356.7	-0.9*
Breast	50.6	0.3	42.1	-2.2*	55.2	-2.6*
Lung and Bronchus	37.6	-1.3*	41.7	-0.6	48.9	-0.6
Colon and Rectum	37.6	-2.4*	39.9	-2.3*	37.7	-1.7*
Prostate ^f	35.5	-3.7*	34.3	-1.9*	32.2	-1.6*
Liver & IBD ^g	14.1	-0.9	19.7	3.0*	17.8	0.7
Non-Hodgkin Lymphoma	13.1	-0.5	13.5	4.8*	15.1	2.1*
Thyroid	12.1	5.5*	12.3	0.1	12.1	2.8*
Stomach	11.9	-3.2*	10.9	2.2*	11.5	-1.6*
Corpus and Uterus, NOS ^f	10.1	2.4*	10.8	2.9	11.3	-1.8*
Pancreas	9.6	0.7	10.0	-3.5	11.3	0.3
Urinary Bladder	9.0	-1.0*	7.8	1.1	10.5	5.4*
Kidney and Renal Pelvis	7.9	2.8*	7.4	0.2	10.4	1.5*
Oral Cavity and Pharynx	7.6	-0.6	7.3	4.8*	10.2	-0.2
Leukemia	7.4	-0.5	7.3	-1.5	6.5	0.4
Ovary ^{fh}	5.1	-1.2	5.9	-3.9	6.1	-2.0*

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

^a Top 15 cancer sites selected based on 2006-2010 age-adjusted rates for the race/ethnic group.

^b Rates are per 100,000 and age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

^c The APC is the Annual Percent Change over the time interval.

^d Trends are based on rates age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

^e Rates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^e Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^f Incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^g The rates for sex-specific cancer sites are calculated using the population for both sexes combined.

^g IBD = Intrahepatic Bile Duct. ONS = Other Nervous System.

^h Ovary excludes borderline cases or histologies 8442, 8451, 8462, 8472, and 8473.

^{*} The APC is significantly different from zero (p<.05).

- Statistic not shown. Rate based on less than 16 cases for the time interval. Trend based on less than 10 cases for at least one year within the time interval.

Table 1.25
Age-Adjusted SEER Incidence Rates and Trends for the Top 15 Cancer Sites^a by Race/Ethnicity

			Males					
All Races			White			Black		
	Rate ^b	APC ^c		Rate ^b	APC ^c		Rate ^b	APC ^c
	2006-2010	2001-2010		2006-2010	2001-2010		2006-2010	2001-2010
All Sites	535.9	-1.1*	All Sites	539.1	-1.1*	All Sites	610.4	-1.9*
Prostate	152.0	-2.3*	Prostate	144.9	-2.5*	Prostate	228.5	-2.6*
Lung and Bronchus	74.3	-2.2*	Lung and Bronchus	74.5	-2.2*	Lung and Bronchus	95.8	-2.8*
Colon and Rectum	52.2	-2.9*	Colon and Rectum	51.3	-3.1*	Colon and Rectum	64.3	-2.4*
Urinary Bladder	36.6	-0.7*	Urinary Bladder	39.8	-0.7*	Kidney and Renal Pelvis	24.1	2.5*
Melanoma of the Skin	27.4	1.8*	Melanoma of the Skin	31.9	1.8*	Urinary Bladder	21.0	0.4
Non-Hodgkin Lymphoma	23.9	0.2	Non-Hodgkin Lymphoma	25.0	0.2	Pancreas	17.6	1.3*
Kidney and Renal Pelvis	21.0	2.2*	Kidney and Renal Pelvis	21.5	2.2*	Non-Hodgkin Lymphoma	17.4	-0.2
Leukemia	16.3	-0.8*	Leukemia	17.2	-0.8*	Stomach	16.1	-2.1*
Oral Cavity and Pharynx	16.2	0.2	Oral Cavity and Pharynx	16.7	0.6*	Liver & IBD ^f	15.1	3.7*
Pancreas	13.9	0.8*	Pancreas	13.8	0.8*	Oral Cavity and Pharynx	14.9	-3.1*
Liver & IBD ^f	11.9	3.8*	Liver & IBD ^f	10.4	4.5*	Myeloma	14.4	-0.4
Stomach	10.4	-1.5*	Stomach	9.2	-1.3*	Leukemia	12.6	-1.9*
Esophagus	7.7	-0.9*	Brain and ONS ^f	8.4	-0.1	Larynx	9.6	-3.7*
Brain and ONS ^f	7.7	-0.3	Esophagus	8.0	-0.2	Esophagus	8.4	-5.0*
Myeloma	7.5	0.6*	Myeloma	7.1	0.7*	Brain and ONS ^f	4.7	-0.2
Asian/Pacific Islander			American Indian/Alaska Native^d			Hispanic^e		
	Rate ^b	APC ^c		Rate ^b	APC ^c		Rate ^b	APC ^c
	2006-2010	2001-2010		2006-2010	2001-2010		2006-2010	2001-2010
All Sites	335.0	-1.8*	All Sites	351.3	-0.7	All Sites	409.7	-1.4*
Prostate	81.8	-3.8*	Prostate	77.8	-2.2*	Prostate	125.8	-3.0*
Lung and Bronchus	50.7	-1.7*	Lung and Bronchus	51.2	-2.3*	Colon and Rectum	45.5	-1.7*
Colon and Rectum	43.8	-2.7*	Colon and Rectum	44.1	-1.2	Lung and Bronchus	40.6	-2.6*
Liver & IBD ^f	21.4	-0.9	Kidney and Renal Pelvis	24.8	2.9	Non-Hodgkin Lymphoma	20.5	0.7
Urinary Bladder	16.1	-1.0*	Liver & IBD ^f	20.6	6.1	Urinary Bladder	20.2	-1.5*
Non-Hodgkin Lymphoma	16.1	-0.2	Non-Hodgkin Lymphoma	14.1	-1.1	Kidney and Renal Pelvis	20.1	2.1*
Stomach	15.5	-3.5*	Urinary Bladder	13.7	-	Liver & IBD ^f	18.3	3.2*
Kidney and Renal Pelvis	11.0	3.2*	Stomach	13.1	-5.4*	Stomach	14.9	-1.3*
Oral Cavity and Pharynx	11.0	0.4	Pancreas	11.4	-	Leukemia	12.2	-0.3
Pancreas	10.4	0.3	Oral Cavity and Pharynx	11.1	2.9	Pancreas	12.1	0.9
Leukemia	9.0	-0.8	Leukemia	8.8	-	Oral Cavity and Pharynx	9.3	-0.1
Thyroid	5.3	4.6*	Esophagus	6.1	-	Myeloma	6.7	-1.3
Myeloma	4.3	1.5	Larynx	4.6	-	Brain and ONS ^f	5.9	-1.3*
Brain and ONS ^f	4.2	0.1	Testis	4.5	-	Esophagus	5.2	-1.0
Esophagus	3.9	-1.3	Melanoma of the Skin	4.1	-	Melanoma of the Skin	4.7	-1.2

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

^a Top 15 cancer sites selected based on 2006-2010 age-adjusted rates for the race/ethnic group.

^b Rates are per 100,000 and age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

^c The APC is the Annual Percent Change over the time interval.

Trends are based on rates age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

^d Rates for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

^e Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^f IBD = Intrahepatic Bile Duct. ONS = Other Nervous System.

* The APC is significantly different from zero (p<.05).

- Statistic not shown. Rate based on less than 16 cases for the time interval. Trend based on less than 10 cases for at least one year within the time interval.

Table 1.26
Age-Adjusted SEER Incidence Rates and Trends for the Top 15 Cancer Sites^a by Race/Ethnicity

Females

All Races	Rate ^b		APC ^c	All Sites	Rate ^b		APC ^c	All Sites	Rate ^b		APC ^c
	2006-2010	2001-2010			2006-2010	2001-2010			2006-2010	2001-2010	
All Sites	411.2	-0.3		All Sites	424.4	-0.3		All Sites	397.5	-0.1	
Breast	123.8	-0.6		Breast	127.4	-0.8*		Breast	121.4	0.4	
Lung and Bronchus	51.9	-0.7*		Lung and Bronchus	54.6	-0.6*		Lung and Bronchus	52.2	-0.2	
Colon and Rectum	39.3	-2.4*		Colon and Rectum	38.4	-2.5*		Colon and Rectum	49.2	-2.4*	
Corpus and Uterus, NOS	24.3	0.9*		Corpus and Uterus, NOS	25.1	0.7*		Corpus and Uterus, NOS	22.2	1.9*	
Thyroid	18.2	6.5*		Melanoma of the Skin	20.0	1.3*		Pancreas	14.3	0.0	
Melanoma of the Skin	16.7	1.2*		Thyroid	19.4	6.6*		Kidney and Renal Pelvis	12.3	3.2*	
Non-Hodgkin Lymphoma	16.4	-0.1		Non-Hodgkin Lymphoma	17.3	0.0		Non-Hodgkin Lymphoma	11.8	-0.3	
Ovary ^g	12.5	-1.7*		Ovary ^g	13.3	-1.7*		Thyroid	10.5	6.1*	
Pancreas	10.9	1.0*		Kidney and Renal Pelvis	10.9	2.3*		Myeloma	10.2	0.7	
Kidney and Renal Pelvis	10.6	2.3*		Pancreas	10.7	1.1*		Ovary ^g	9.7	-0.9	
Leukemia	10.0	-0.4		Leukemia	10.5	-0.4		Cervix Uteri	9.6	-3.0*	
Urinary Bladder	8.9	-0.9*		Urinary Bladder	9.5	-0.9*		Stomach	8.7	-1.2	
Cervix Uteri	7.9	-1.7*		Cervix Uteri	7.9	-1.4*		Leukemia	7.8	-1.6*	
Oral Cavity and Pharynx	6.2	-0.2		Oral Cavity and Pharynx	6.3	0.1		Urinary Bladder	7.1	-1.2	
Brain and ONS ^f	5.4	-0.4		Brain and ONS ^f	6.0	-0.4		Oral Cavity and Pharynx	5.4	-1.4	
Asian/Pacific Islander				American Indian/Alaska Native ^d				Hispanic ^e			
	Rate ^b	APC ^c		Rate ^b	APC ^c		Rate ^b	APC ^c			
	2006-2010	2001-2010		2006-2010	2001-2010		2006-2010	2001-2010			
All Sites	291.5	-0.1		All Sites	306.5	-0.4		All Sites	323.2	-0.4*	
Breast	91.8	0.2		Breast	77.1	-0.5		Breast	90.8	-0.5	
Colon and Rectum	32.7	-2.0*		Colon and Rectum	36.6	-3.3*		Colon and Rectum	31.6	-1.8*	
Lung and Bronchus	28.1	-0.4		Lung and Bronchus	35.7	-2.0		Lung and Bronchus	26.3	-0.6	
Corpus and Uterus, NOS	18.6	2.4*		Corpus and Uterus, NOS	20.3	3.1		Corpus and Uterus, NOS	19.4	1.7*	
Thyroid	17.9	5.7*		Kidney and Renal Pelvis	15.6	3.0		Thyroid	16.4	5.7*	
Non-Hodgkin Lymphoma	10.9	-0.8		Thyroid	11.0	4.7*		Non-Hodgkin Lymphoma	15.6	0.7	
Ovary ^g	9.4	-1.2		Non-Hodgkin Lymphoma	10.8	0.8		Ovary ^g	11.3	-1.8*	
Stomach	9.3	-2.6*		Ovary ^g	10.7	-3.7		Kidney and Renal Pelvis	11.1	1.9*	
Pancreas	8.9	1.0		Pancreas	10.5	1.9		Cervix Uteri	10.9	-4.2*	
Liver & IBD ^f	8.2	-0.9		Liver & IBD ^f	7.7	2.8		Pancreas	10.6	-0.2	
Cervix Uteri	6.6	-3.9*		Stomach	7.7	-1.1		Leukemia	8.7	-0.1	
Leukemia	6.1	0.0		Cervix Uteri	7.3	0.1		Stomach	8.6	-2.3*	
Kidney and Renal Pelvis	5.5	2.4		Leukemia	6.2	-2.3		Liver & IBD ^f	6.9	1.8	
Oral Cavity and Pharynx	4.9	-2.1*		Oral Cavity and Pharynx	4.3	-		Urinary Bladder	5.2	-2.3*	
Urinary Bladder	3.9	-0.9		Myeloma	3.7	-		Brain and ONS ^f	4.7	-1.1	

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

^a Top 15 cancer sites selected based on 2006-2010 age-adjusted rates for the race/ethnic group.

^b Rates are per 100,000 and age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

^c The APC is the Annual Percent Change over the time interval.

Trends are based on rates age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

^d Rates for American Indian/Alaska Native are based on the CHSDA(Contract Health Service Delivery Area) counties.

^e Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^f IBD = Intrahepatic Bile Duct. ONS = Other Nervous System.


^g Ovary excludes borderline cases or histologies 8442, 8451, 8462, 8472, and 8473.

* The APC is significantly different from zero (p<.05).

- Statistic not shown. Rate based on less than 16 cases for the time interval. Trend based on less than 10 cases for at least one year within the time interval.

Figure 1.13

SEER Incidence 2001-2010 Males by Race/Ethnicity



Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG).

Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103).

Regression lines are calculated using the Joinpoint Regression Program Version 4.0.3, April 2013, National Cancer Institute.


^a Incidence rates for American Indian/Alaska Native (AI/AN) are based on the CHSDA (Contract Health Service Delivery Area) counties.

^b Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

Incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

Figure 1.14

SEER Incidence 2001-2010 Females by Race/Ethnicity



Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey and Georgia excluding ATL/RG). Rates are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1103).

Regression lines are calculated using the Joinpoint Regression Program Version 4.0.3, April 2013, National Cancer Institute.

^a Incidence rates for American Indian/Alaska Native (AI/AN) are based on the CHSDA (Contract Health Service Delivery Area) counties.

^b Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives. Incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.